NASDAQ · ESLA
Estrella Immunopharma, Inc.
$0.73-$0.09 (-11.32%)
Estrella Immunopharma, Inc.’s quoted price sits in the lower half of its reported 52-week range, 76.87% below the high.
Loading market information…
NASDAQ · INM · USD
Stock price, earnings
Quote as of Oct 29, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
InMed Pharmaceuticals Inc.’s quoted price sits in the upper half of its reported 52-week range, 30.26% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
InMed Pharmaceuticals Inc.’s next earnings report is currently expected on Nov 5, 2026, with estimated earnings per share of -$94.44. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow InMed Pharmaceuticals Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
InMed Pharmaceuticals Inc. operates as a clinical-stage pharmaceutical firm, concentrating its efforts on the investigation and creation of therapeutic solutions derived from cannabinoids. Its primary product, INM-755, is a cannabinol-infused topical cream that is currently progressing through its second Phase I clinical trial for the management of epidermolysis bullosa. Beyond this lead candidate, the company is also developing INM-088, which is undergoing preclinical studies for glaucoma treatment, and INM-405, intended for pain relief. Its broader development pipeline encompasses cannabinoid-based interventions for a variety of medical conditions, with a particular focus on dermatological and ocular disorders. Furthermore, InMed is involved in critical IND-enabling pharmacology and preclinical toxicology research. It is also pioneering IntegraSyn, an innovative integrated biosynthesis approach designed to produce pharmaceutical-grade cannabinoids efficiently. The company maintains a research partnership with BayMedica Inc. to collaborate on the formulation and assessment of novel cannabinoid therapeutics. Established in 1981, the company is headquartered in Vancouver, Canada. It operated under the name Cannabis Technologies Inc. before officially rebranding as InMed Pharmaceuticals Inc. in October 2014.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 03:56 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| -$3.64 |
| $1.24M+10.04% vs estimate |
| Q1 2025 | Nov 14, 2024 | -$0.54-3,619.48% vs estimate | $901.86K-34.98% vs estimate |
|---|
THE ANALYST VIEW
2 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$0.73-$0.09 (-11.32%)
Estrella Immunopharma, Inc.’s quoted price sits in the lower half of its reported 52-week range, 76.87% below the high.
$8.72+$0.39 (+4.68%)
Kazia Therapeutics Ltd ADR’s quoted price sits in the lower half of its reported 52-week range, 49.89% below the high.
$1.38-$0.08 (-5.48%)
BioVie Inc.’s quoted price sits in the lower half of its reported 52-week range, 63.59% below the high.
$4.77+$0.26 (+5.76%)
CNS Pharmaceuticals, Inc.’s quoted price sits in the lower half of its reported 52-week range, 54.74% below the high.
$4.63+$0.81 (+21.05%)
Galmed Pharmaceuticals Ltd.’s quoted price sits in the lower half of its reported 52-week range, 64.92% below the high.
$2.04-$0.06 (-2.86%)
Jaguar Health, Inc.’s quoted price sits in the lower half of its reported 52-week range, 99.81% below the high.
$1.57-$0.06 (-3.38%)
GRI Bio, Inc.’s quoted price sits in the lower half of its reported 52-week range, 97.55% below the high.
$1.25-$0.09 (-6.72%)
Silo Pharma, Inc.’s quoted price sits in the lower half of its reported 52-week range, 88.02% below the high.
